Cargando…

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma

Uveal melanoma (UM) is the most common malignant tumor of the eye. Recently, we have established that 46% of UM specimens express LHRH receptors. This finding supports the idea of a LHRH receptor-targeted therapy of UM patients. Cytotoxic analog of LHRH, AEZS-108 exhibits effective anti-cancer activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fodor, Klara, Dobos, Nikoletta, Schally, Andrew, Steiber, Zita, Olah, Gabor, Sipos, Eva, Szekvolgyi, Lorant, Halmos, Gabor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968782/ https://www.ncbi.nlm.nih.gov/pubmed/32010430 http://dx.doi.org/10.18632/oncotarget.27431

Ejemplares similares

Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma
por: Sipos, Eva, et al.
Publicado: (2017)

Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma
por: Fodor, Klára, et al.
Publicado: (2020)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines
por: Sipos, Eva, et al.
Publicado: (2018)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108
por: Szepeshazi, Karoly, et al.
Publicado: (2013)

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)
por: Szepeshazi, Karoly, et al.
Publicado: (2012)

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma
por: Harda, Kristof, et al.
Publicado: (2018)

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
por: Popovics, Petra, et al.
Publicado: (2014)

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone
por: Jaszberenyi, Miklos, et al.
Publicado: (2013)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
por: Hornyák, Lilla, et al.
Publicado: (2018)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases
por: Halász, László, et al.
Publicado: (2017)

Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies
por: Trencsényi, György, et al.
Publicado: (2023)

NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review
por: Trencsényi, György, et al.
Publicado: (2023)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

LHRH agonists and the prevention of breast and ovarian cancer.
por: Pike, M. C., et al.
Publicado: (1989)

Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment
por: Vagia, Elena, et al.
Publicado: (2015)

Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide
por: Couty, Mickael, et al.
Publicado: (2021)

Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study
por: Morote, Juan, et al.
Publicado: (2022)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

Histone H3 Lysine 56 Acetylation Is Required for Formation of Normal Levels of Meiotic DNA Breaks in S. cerevisiae
por: Karányi, Zsolt, et al.
Publicado: (2020)

Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
por: Castet, Florian, et al.
Publicado: (2019)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
por: Harda, Kristof, et al.
Publicado: (2020)

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
por: Tree, Alison, et al.
Publicado: (2022)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution
por: Brouwer, Niels J., et al.
Publicado: (2019)

Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
por: Szabó, Zoltán, et al.
Publicado: (2021)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

A single active catalytic site is sufficient to promote transport in P-glycoprotein
por: Bársony, Orsolya, et al.
Publicado: (2016)

Testing the Applicability of MALDI-TOF MS as an Alternative Stock Identification Method in a Cryptic Species Complex
por: Maasz, Gabor, et al.
Publicado: (2020)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches
por: Szabo, Zsuzsanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sscnn69c9cq2pstv05khvl58i2